1-11 of 11
Vincent Ribrag
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 447–459.
https://doi.org/10.1158/1078-0432.CCR-20-2657
Published: 19 January 2021
View article titled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers
Open the PDF for Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

Clémentine Sarkozy, Franck Morschhauser, Sydney Dubois, Thierry Molina, Jean Marie Michot, Peggy Cullières-Dartigues, Benjamin Suttle, Lionel Karlin, Steven Le Gouill, Jean-Michel Picquenot, Romain Dubois, Hervé Tilly, Charles Herbaux, Fabrice Jardin, Gilles Salles, Vincent Ribrag
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3145–3153.
https://doi.org/10.1158/1078-0432.CCR-19-3741
Published: 01 July 2020
View article titled, A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features
Open the PDF for A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Timothy A. Yap, Jane N. Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean-Marie Michot, John P. Leonard, Vincent Ribrag, Michael T. McCabe, Caretha L. Creasy, Melissa Stern, Teodora Pene Dumitrescu, Xiaowei Wang, Steve Frey, Jennifer Carver, Thierry Horner, Choon Oh, Ahmed Khaled, Arindam Dhar, Peter W.M. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7331–7339.
https://doi.org/10.1158/1078-0432.CCR-18-4121
Published: 13 December 2019
View article titled, Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Open the PDF for Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andrea Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Sophie Postel-Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean-Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 946–956.
https://doi.org/10.1158/1078-0432.CCR-18-0793
Published: 01 February 2019
View article titled, Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Open the PDF for Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation in another window
Includes: Supplementary data
Journal Articles

Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma

Fabienne Desmots, Mikaël Roussel, Céline Pangault, Francisco Llamas-Gutierrez, Cédric Pastoret, Eric Guiheneuf, Jérôme Le Priol, Valérie Camara-Clayette, Gersende Caron, Catherine Henry, Marc-Antoine Belaud-Rotureau, Pascal Godmer, Thierry Lamy, Fabrice Jardin, Karin Tarte, Vincent Ribrag, Thierry Fest
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 735–746.
https://doi.org/10.1158/1078-0432.CCR-18-1153
Published: 15 January 2019
View article titled, Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma
Open the PDF for Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma in another window
Includes: Supplementary data
Journal Articles

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

Anastasios Stathis, Alexia Iasonos, John F. Seymour, Catherine Thieblemont, Vincent Ribrag, Emanuele Zucca, Anas Younes
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 2993–2998.
https://doi.org/10.1158/1078-0432.CCR-17-3021
Published: 01 July 2018
View article titled, Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
Open the PDF for Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas in another window
Journal Articles

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6411–6420.
https://doi.org/10.1158/1078-0432.CCR-17-0613
Published: 31 October 2017
View article titled, Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Open the PDF for Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam S. Crystal, Sudha Parasuraman, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5696–5705.
https://doi.org/10.1158/1078-0432.CCR-16-1248
Published: 30 November 2016
View article titled, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, Max S. Topp, Caly Chien, Shobha Seetharam, Regina Aquino, Sonja Kotoulek, Carla J. de Boer, Andreas Engert
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (8): 1843–1850.
https://doi.org/10.1158/1078-0432.CCR-14-1845
Published: 14 April 2015
View article titled, An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Open the PDF for An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haioun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard, Bertrand Coiffier
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 213–220.
https://doi.org/10.1158/1078-0432.CCR-13-0580
Published: 05 January 2014
View article titled, A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Open the PDF for A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

High Level of Glutathione- S -Transferase π Expression in Mantle Cell Lymphomas

Annelise Bennaceur-Griscelli, Jacques Bosq, Serge Koscielny, François Lefrère, Ali Turhan, Nicole Brousse, Olivier Hermine, Vincent Ribrag
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 3029–3034.
https://doi.org/10.1158/1078-0432.CCR-03-0554
Published: 06 May 2004
View article titled, High Level of Glutathione- <em>S</em> -Transferase π Expression in Mantle Cell Lymphomas
Open the PDF for High Level of Glutathione- <em>S</em> -Transferase π Expression in Mantle Cell Lymphomas in another window